Emerging immunotherapy for HCC: A guide for hepatologists
Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas, Peter Robert Galle – 6 March 2022 – HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the advanced stages of disease.